The challenge
Inbeeo supported a mid-sized pharmaceutical client in expanding their global footprint in rare diseases by targeting low- and middle-income countries (LMICs).
The client sought a strategic Global Pricing Policy tailored to their chronic rare disease treatments, company size, and focus on balancing equitable access with commercial sustainability.
The approach
To inform the Global Pricing Policy for LMICs, Inbeeo conducted a company benchmark, selecting 5 companies with a similar portfolio, with presence across 10 priority markets.
Together, the 5 companies, represented >20 relevant analogue products. For each of the >20 products, in each of the 10 markets Inbeeo analysed:
- Access status
- Access pathways
- Access timelines
- Pricing
- Commercialisation
Insights and recommendations were tested and enriched through interviews with two former pharmaceutical industry professionals.
The impact
The research yielded key learnings and actionable recommendations on:
- Product Selection
- Market Selection
- Pathway Selection
- Pricing Approaches
- Partnering Approaches
As a next step, Inbeeo supported the client in operationalizing its Global Equity Pricing Principle to further inform the Global Pricing Policy for LMICs.
